These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

35 related articles for article (PubMed ID: 15167909)

  • 1. Reliability of flow-cytometry in diagnosis and prognostic stratification of myelodysplastic syndromes: correlations with morphology and mutational profile.
    Guarnera L; Fabiani E; Attrotto C; Hajrullaj H; Cristiano A; Latagliata R; Fenu S; Buccisano F; Irno-Consalvo M; Conti C; Voso MT; Maurillo L
    Ann Hematol; 2023 Nov; 102(11):3015-3023. PubMed ID: 37535147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutation landscape of normal karyotype myelodysplastic syndromes and their prognostic impact.
    Wang W; Zhang Y; Yang W; Han Y; Jiang L; Liu X; Lang W; Luo Y; Zhu S; Zhou X; Wang L; Ye L; Ma L; Tong H
    Am J Hematol; 2024 Feb; 99(2):E51-E54. PubMed ID: 37988226
    [No Abstract]   [Full Text] [Related]  

  • 3. Myelodysplastic Syndrome: Diagnosis and Screening.
    Tria FP; Ang DC; Fan G
    Diagnostics (Basel); 2022 Jun; 12(7):. PubMed ID: 35885487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions.
    Valent P; Orazi A; Steensma DP; Ebert BL; Haase D; Malcovati L; van de Loosdrecht AA; Haferlach T; Westers TM; Wells DA; Giagounidis A; Loken M; Orfao A; Lübbert M; Ganser A; Hofmann WK; Ogata K; Schanz J; Béné MC; Hoermann G; Sperr WR; Sotlar K; Bettelheim P; Stauder R; Pfeilstöcker M; Horny HP; Germing U; Greenberg P; Bennett JM
    Oncotarget; 2017 Sep; 8(43):73483-73500. PubMed ID: 29088721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicentric study underlining the interest of adding CD5, CD7 and CD56 expression assessment to the flow cytometric Ogata score in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.
    Bardet V; Wagner-Ballon O; Guy J; Morvan C; Debord C; Trimoreau F; Benayoun E; Chapuis N; Freynet N; Rossi C; Mathis S; Gourin MP; Toma A; Béné MC; Feuillard J; Guérin E; ;
    Haematologica; 2015 Apr; 100(4):472-8. PubMed ID: 25637056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered immunophenotypic features of peripheral blood platelets in myelodysplastic syndromes.
    Sandes AF; Yamamoto M; Matarraz S; Chauffaille Mde L; Quijano S; López A; Oguro T; Kimura EY; Orfao A
    Haematologica; 2012 Jun; 97(6):895-902. PubMed ID: 22271903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes.
    van de Loosdrecht AA; Alhan C; Béné MC; Della Porta MG; Dräger AM; Feuillard J; Font P; Germing U; Haase D; Homburg CH; Ireland R; Jansen JH; Kern W; Malcovati L; Te Marvelde JG; Mufti GJ; Ogata K; Orfao A; Ossenkoppele GJ; Porwit A; Preijers FW; Richards SJ; Schuurhuis GJ; Subirá D; Valent P; van der Velden VH; Vyas P; Westra AH; de Witte TM; Wells DA; Loken MR; Westers TM
    Haematologica; 2009 Aug; 94(8):1124-34. PubMed ID: 19546437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flow cytometric immunophenotyping: emerging as an important diagnostic tool in the evaluation of cytopenic patients.
    Stetler-Stevenson M
    Leuk Res; 2009 Aug; 33(8):1020-1. PubMed ID: 19327830
    [No Abstract]   [Full Text] [Related]  

  • 9. SALL4, a novel oncogene, is constitutively expressed in human acute myeloid leukemia (AML) and induces AML in transgenic mice.
    Ma Y; Cui W; Yang J; Qu J; Di C; Amin HM; Lai R; Ritz J; Krause DS; Chai L
    Blood; 2006 Oct; 108(8):2726-35. PubMed ID: 16763212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical implications of blast immunophenotypes in myelodysplastic syndromes.
    Ogata K; Yoshida Y
    Leuk Lymphoma; 2005 Sep; 46(9):1269-74. PubMed ID: 16109603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surface marker abnormalities in myelodysplastic syndromes.
    Elghetany MT
    Haematologica; 1998 Dec; 83(12):1104-15. PubMed ID: 9949628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of immunophenotype on prognosis of patients with myelodysplastic syndromes. Its value in patients without karyotypic abnormalities.
    Arroyo JL; Fernández ME; Hernández JM; Orfao A; San Miguel JF; del Cañizo MC
    Hematol J; 2004; 5(3):227-33. PubMed ID: 15167909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving the differential diagnosis between myelodysplastic syndromes and reactive peripheral cytopenias by multiparametric flow cytometry: the role of B-cell precursors.
    Reis-Alves SC; Traina F; Metze K; Lorand-Metze I
    Diagn Pathol; 2015 Apr; 10():44. PubMed ID: 25924846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia: a single-institution experience.
    Plesa C; Chelghoum Y; Plesa A; Elhamri M; Tigaud I; Michallet M; Dumontet C; Thomas X
    Cancer; 2008 Feb; 112(3):572-80. PubMed ID: 18085638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cytogenetic characteristics of hematopoietic and stromal progenitor cells in myelodysplastic syndrome].
    Pimenova MA; Parovichnikova EN; Kokhno AV; Domracheva EV; Manakova TE; Mal'tseva IuS; Konnova ML; Shishigina LA; Savchenko VG
    Ter Arkh; 2013; 85(7):34-42. PubMed ID: 24137945
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.